Carroll, Jason S.
Hickey, Theresa E.
Tarulli, Gerard A.
Williams, Michael
Tilley, Wayne D.
Article History
First Online: 25 November 2016
Change Date: 30 November 2016
Change Type: Corrigendum
Change Details: In this article, the sentence "The T47D-Y derivatives express substantially lower levels of ER than endogenous T47D cells." on page 8 was incorrectly referenced. The correct references are 119 and 135, not 23 and 135. This has been corrected online.
Competing interests
: Michael Williams has represented women with legal claims for breast cancer induced by medroxyprogesterone acetate or norethindrone acetate when used as menopausal hormone therapy. The other authors declare no potential competing interests.